Heart failure & cardiomyopathies
Late gadolinium enhancement dispersion for predicting malignant arrhythmic events in patient with non-ischaemic dilated cardiomyopathy
Authors' conclusion
GDS is a useful marker to identify DCM patients at higher risk for malignant arrhythmic events regardless of LVEF and extent of LGE.
Study context
- Population
- Patients with non-ischaemic dilated cardiomyopathy (DCM) undergoing cardiac magnetic resonance imagingfinal population (mean age was 56 ± 15 years)
- Participants
- 510 patients
- Comparison
- Patients with Global Dispersion Score (GDS) > 0.10 vs those with lower values of GDS
- Outcome
- Combined endpoint of sudden cardiac death and appropriate implantable cardioverter-defibrillator intervention (Kaplan-Meier analysis)
- Follow-up
- 3.3 years (2 to 6 years)
Main finding
As reported in the abstract
- GDS > 0.10 vs lower values of GDS: P < 0.0001
- Kaplan-Meier analysis
Further findings
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| Independent predictor of events (multivariate analysis)Multivariate analysis | 2.9 (1.7–5) | P = 0.0002 | |
| 0.20.5125Hazard ratio (log scale) |
Baseline characteristics
- Left ventricular ejection fraction (LVEF) >35%
- 241 patients (47%)
- LGE present
- 225 patients (45%)
- Median extent of LGE (% of LV mass)
- 12% [interquartile range (IQR) 6-20%]
- GDS among patients with positive LGE
- 0.14 (IQR 0.08-0.20)
Malignant ventricular arrhythmias during follow-up
- Patients with malignant ventricular arrhythmias
- 81
- SCD
- 8
- Appropriate ICD interventions
- 73
Prognostic value of GDS in subgroups with LVEF ≤ 35% and >35%
- Prognostic value of GDS confirmed in subgroups of patients with LVEF ≤ 35% and >35%
Original publication
Late gadolinium enhancement dispersion for predicting malignant arrhythmic events in patient with non-ischaemic dilated cardiomyopathy. Eur Heart J Cardiovasc Imaging. Published 17 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →